Evidence map›Paper›PMID 19763271›Full record

ArticlePLoS pathogens2009

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Penny L Moore, Nthabeleng Ranchobe, Bronwen E Lambson, Elin S Gray, Eleanor Cave, Melissa-Rose Abrahams, Gama Bandawe, Koleka Mlisana, Salim S Abdool Karim, Carolyn Williamson and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 230 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Inspecting the interaction between human immunodeficiency virus and the immune system through genetic turnover.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Penny L MooreAIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa.
Nthabeleng Ranchobe
Bronwen E Lambson
Elin S Gray
Eleanor Cave
Melissa-Rose Abrahams
Gama Bandawe
Koleka Mlisana
Salim S Abdool Karim
Carolyn Williamson
Lynn Morris
CAPRISA 002 Study
NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI)
National Institute for Communicable DiseasesUniversity of Cape Town · ZAUniversity of KwaZulu-Natal · ZAUniversity of the Witwatersrand · ZA

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI DENNY, THOMAS · 2006 to 2011
$290.5M
The Viral Set Point in HIV-1 Subtype C InfectionU19AI051794 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI ABDOOL KARIM, SALIM S · 2002 to 2007
$22.5M
Viral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAHN, BEATRICE H · 2005 to 2005
$14.9M
TUBERCULOSIS SUPPLEMENTD43TW000231 · FIC · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ABDOOL KARIM, QUARRAISHA · 1993 to 2014
$13.1M
FIC NIH HHS D43 TW000231FIC NIH HHS D43 TW00231NIAID NIH HHS AI067854NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI051794NIAID NIH HHS U19 AI067854Wellcome Trust 089933
6 · The paper itself

Abstract

We previously showed that HIV-1 subtype C viruses elicit potent but highly type-specific neutralizing antibodies (nAb) within the first year of infection. In order to determine the specificity and evolution of these autologous nAbs, we examined neutralization escape in four individuals whose responses against the earliest envelope differed in magnitude and potency. Neutralization escape occurred in all participants, with later viruses showing decreased sensitivity to contemporaneous sera, although they retained sensitivity to new nAb responses. Early nAb responses were very restricted, occurring sequentially and targeting only two regions of the envelope. In V1V2, limited amino acid changes often involving indels or glycans, mediated partial or complete escape, with nAbs targeting the V1V2 region directly in 2 cases. The alpha-2 helix of C3 was also a nAb target, with neutralization escape associated with changes to positively charged residues. In one individual, relatively high titers of anti-C3 nAbs were required to drive genetic escape, taking up to 7 weeks for the resistant variant to predominate. Thereafter titers waned but were still measurable. Development of this single anti-C3 nAb specificity was associated with a 7-fold drop in HIV-1 viral load and a 4-fold rebound as the escape mutation emerged. Overall, our data suggest the development of a very limited number of neutralizing antibody specificities during the early stages of HIV-1 subtype C infection, with temporal fluctuations in specificities as escape occurs. While the mechanism of neutralization escape appears to vary between individuals, the involvement of limited regions suggests there might be common vulnerabilities in the HIV-1 subtype C transmitted envelope.

Indexed as

Antibody DiversityMutationAmino Acid MotifsAmino Acid SequenceAntibodies, NeutralizingCell LineEpitopesFemaleHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHost-Pathogen InteractionsHumansMolecular Sequence DataRNA, ViralAntibodies, NeutralizingEpitopesgp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120RNA, Viral

Identifiers

PMID19763271
PMCPMC2742164
OpenAlexW2085166312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.